TRT and peptide stacking: what the science actually supports
Quick answer
PT-141 (bremelanotide) is a melanocortin receptor agonist with clinical trial data supporting improvements in erectile rigidity and duration in men with diagnosed erectile dysfunction, but it is FDA-approved only for hypoactive sexual desire disorder in premenopausal women. The video presents findings from controlled laboratory studies, including RigiScan-measured rigidity data, as broadly applicable performance enhancement claims for healthy men, which overstates what the evidence actually supports. Men interested in this compound should consult a licensed provider, as compounded versions are not FDA-approved and carry documented side effects including nausea and transient blood pressure elevation.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team· This is not a transcript. It is our independent review of the video above.
What did @jasonposton_ actually say?
Jason Poston promoted PT-141 (bremelanotide) as a "sex-enhancing peptide" that makes you "bigger, harder, and harder for a lot longer." He cited a specific data point: a placebo group averaged erections of 22 minutes, while PT-141 users averaged 140 minutes. He also claimed users experienced "60% more rigidity." The framing was casual and personal, positioning this as a lifestyle upgrade rather than a medical treatment.
He did not mention that PT-141 is FDA-approved only for premenopausal women with hypoactive sexual desire disorder (HSDD), sold under the brand name Vyleesi. He also did not clarify dosing, side effect profiles, or the fact that this compound sits in a legally complicated space for men specifically.
Does the science back this up?
Partly, but the numbers he cited come from a narrow, controlled context that he stripped of important caveats. The claim about erection duration and rigidity has roots in real clinical research, but applying it the way he did flattens a lot of meaningful nuance.
PT-141 is a melanocortin receptor agonist. It works centrally, through the brain, not through vascular mechanisms the way PDE5 inhibitors like sildenafil do. Early-phase trials in men with erectile dysfunction did show promising results. Rosen et al. (2004, International Journal of Impotence Research) found that intranasal bremelanotide produced statistically significant improvements in erectile function compared to placebo, including duration and rigidity scores. A separate study by Diamond et al. (2004, same journal) reported similar findings in men with both organic and psychogenic ED.
The specific figures Poston cited, 22 minutes versus 140 minutes, and 60% greater rigidity, appear to reference measurements taken during visual sexual stimulation in a clinical lab. That is a very different context than real-world use. Stimulation was controlled, timing was measured by RigiScan devices, and participants had documented ED. Extrapolating those numbers to healthy men seeking performance enhancement is a stretch the original researchers did not make.
What did they get wrong (or right)?
He got the basic mechanism directionally right. PT-141 does work through melanocortin receptors and does appear to improve erectile function in men with ED. The data he referenced is real, not fabricated. Credit where it is due.
What he got wrong is significant, though. First, he presents this as a general male enhancement tool rather than a compound studied in men with documented dysfunction. Second, his claim that it makes you "bigger" has no clinical backing whatsoever. PT-141 affects arousal and rigidity; it does not increase penile size. That is simply inaccurate. Third, he does not mention that the compound was dropped from development for men after the FDA approved it only for women, partly due to a side effect profile that included nausea, flushing, and transient blood pressure increases. Kingsberg et al. (2019, Obstetrics and Gynecology) documented these effects in the female approval trials. Fourth, the peptide is not FDA-approved for men, and compounded versions exist in a legally gray regulatory space. None of that context appears in the video.
What should you actually know?
PT-141 has real science behind it, but the science is narrower than this video implies. If you have diagnosed erectile dysfunction, there is peer-reviewed evidence suggesting bremelanotide may help, though it is not approved for that indication in the United States for men. If you are a healthy man looking for a recreational performance boost, the evidence base does not cleanly support that use, and the side effect and regulatory picture is murkier than a TikTok caption suggests.
The most important things to understand before considering PT-141:
- It is not FDA-approved for men in any indication as of 2024.
- Compounded versions vary in quality and are not equivalent to any approved pharmaceutical product.
- Common side effects include nausea, facial flushing, and blood pressure changes, even at studied doses.
- The "bigger" claim has no clinical evidence. Rigidity and arousal are not the same as anatomical size.
- Anyone considering this should speak with a licensed provider who can evaluate their full health history, not act on a social media recommendation.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Access rules depend on the compound and patient situation
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 9 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For TRT and peptide stacking: what the science actually supports, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
SCENESSE (afamelanotide implant) FDA Prescribing Information
Afamelanotide (an alpha-MSH analog) is the only FDA-approved melanocortin peptide of this class, and only to increase pain-free light exposure in erythropoietic protoporphyria, not for cosmetic tanning.
FDA
Afamelanotide for Erythropoietic Protoporphyria
Randomized placebo-controlled trials (NEJM) behind the afamelanotide approval; this is the legitimate human melanocortin evidence, distinct from unapproved tanning peptides.
PubMed
VYLEESI (bremelanotide injection) FDA Prescribing Information
Bremelanotide (PT-141) is FDA-approved as Vyleesi for acquired, generalized hypoactive sexual desire disorder in premenopausal women; approval is limited to that indication.
FDA
Bremelanotide for Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials
Pivotal RECONNECT studies: two double-blind placebo-controlled Phase 3 trials (1,267 women) showing improved sexual desire and reduced distress versus placebo.
PubMed
Provider decision path
Use local research to choose a safer review path
Direct answer
TRT and peptide stacking: what the science actually supports is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.
Evidence check
Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.
Safety check
Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.
Next step
Compare providers, services and access requirements in the directory before contacting a suitable care team.
Claim path
Keep researching this testosterone and trt video claims cluster
Best for searchers turning TRT social claims into a safer lab-backed provider discussion.
Claim verdict
The useful answer behind this video
Claim being checked
PT-141 (bremelanotide) is a melanocortin receptor agonist with clinical trial data supporting improvements in erectile rigidity and duration in men with diagnosed erectile dysfunction, but it is FDA-approved only for hypoactive sexual desire disorder in premenopausal women.
FormBlends verdict
PT-141 (bremelanotide) is a melanocortin receptor agonist with clinical trial data supporting improvements in erectile rigidity and duration in men with diagnosed erectile dysfunction, but it is FDA-approved only for hypoactive sexual desire disorder in premenopausal women. The video presents findings from controlled laboratory studies, including RigiScan-measured rigidity data, as broadly applicable performance enhancement claims for healthy men, which overstates what the evidence actually supports. Men interested in this compound should consult a licensed provider, as compounded versions are not FDA-approved and carry documented side effects including nausea and transient blood pressure elevation.
Patient-safe next step
Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- PT-141 (bremelanotide) is a melanocortin receptor agonist with clinical trial data supporting improvements in erectile rigidity and duration in men with diagnosed erectile dysfunction, but it is FDA-approved only for hypoactive sexual desire disorder in premenopausal women. The video presents findings from controlled laboratory studies, including RigiScan-measured rigidity data, as broadly applicable performance enhancement claims for healthy men, which overstates what the evidence actually supports. Men interested in this compound should consult a licensed provider, as compounded versions are not FDA-approved and carry documented side effects including nausea and transient blood pressure elevation.
- PT-141 (bremelanotide) is FDA-approved only for premenopausal women with HSDD under the brand name Vyleesi; it holds no approved indication for men as of 2024.
- Rosen et al. (2004) and Diamond et al. (2004) in the International Journal of Impotence Research found bremelanotide improved erectile rigidity and duration in men with diagnosed ED under controlled lab conditions, not in healthy men seeking enhancement.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compound access, legal status, and product quality still need a separate safety check.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.
Start provider reviewWhat You'll Learn
- PT-141 (bremelanotide) is FDA-approved only for premenopausal women with HSDD under the brand name Vyleesi; it holds no approved indication for men as of 2024.
- Rosen et al. (2004) and Diamond et al. (2004) in the International Journal of Impotence Research found bremelanotide improved erectile rigidity and duration in men with diagnosed ED under controlled lab conditions, not in healthy men seeking enhancement.
- The claim that PT-141 increases penile size is unsupported by any published clinical data. Rigidity improvement and anatomical size are not the same thing.
- Documented side effects from bremelanotide trials include nausea in up to 40% of subjects, facial flushing, and transient increases in blood pressure (Kingsberg et al., 2019, Obstetrics and Gynecology).
- Compounded versions of PT-141 available through telehealth platforms are not FDA-approved and cannot be considered equivalent to any brand-name pharmaceutical product.
- The 22-minute vs. 140-minute erection duration data referenced in the video comes from RigiScan measurements under controlled visual sexual stimulation in a clinical trial setting, not from typical real-world use.
- Anyone considering PT-141 should consult a licensed medical provider for a full health evaluation, particularly given its blood pressure effects and the lack of long-term safety data in men.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
Jason Poston · TikTok creator
98.9K views on this video
Link in my bio to doctor prescribed peptides. #postonstrong #peptide #peptidetherapy #trt #telehealth
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by Jason Poston, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.